MedTrace Logo

The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer

NCT05351398 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2022-04-28

No results posted yet for this study

Summary

Neoadjuvant chemotherapy has become the mainstream recommended treatment for advanced gastric cancer. However, due to the heterogeneity of gastric cancer, part of some patients fail to benefit from the treatment. This project aims to compare the clinical efficacy of individualized neoadjuvant therapy based on patient-derived organoid drug sensitivity assay and traditional regimen, exploring the advantages and disadvantages of these two treatments. And access the safety and clinical value of the personalized neoadjuvant therapy based on patient-derived organoid drug sensitivity assay in advanced gastric cancer.

Conditions

  • Advanced Gastric Carcinoma

Interventions

DRUG

PDO group

Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.

DRUG

Traditional group

Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.

Sponsors & Collaborators

  • Ruijin Hospital

    collaborator OTHER

  • Shanghai OneTar Biomedicine Co., Ltd.

    collaborator UNKNOWN

  • Shanghai Minimally Invasive Surgery Center

    lead OTHER

Principal Investigators

  • Jing Sun, PhD · Shanghai Jiao Tong University School of Medicine

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-30
Primary Completion
2023-06-30
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05351398 on ClinicalTrials.gov